The combined annual revenue of just two GLP-1 peptides, semaglutide and tirzepatide, is projected to exceed $55 billion. This figure nearly rivals the revenue of the entire AI large language model industry, demonstrating the massive, often underestimated, economic scale of the market for effective metabolic health solutions.

While AI dominates headlines, GLP-1s offer more immediate and tangible improvements to human health and quality of life. The market impact of solving pervasive health crises like obesity, addiction, and heart disease may ultimately dwarf the current perceived value of AI.

Max Marchione consistently uses the success of GLP-1 agonists (e.g., Ozempic) to counter the claim that peptides are an inferior drug class. By highlighting that perhaps the most impactful drug of the modern era is a peptide, he argues that the entire category holds immense, untapped potential that cannot be dismissed.

Originally for diabetes, GLP-1s' broad positive effects on inflammation, heart, and brain function position them as the first mainstream drugs for human enhancement and longevity, moving beyond simple disease management.

Scott Galloway argues that GLP-1 drugs (like Ozempic) will have a greater impact on people's lives and ultimately create more shareholder value than artificial intelligence. When asked, individuals who use both would likely give up AI before their GLP-1 medication, highlighting its profound personal impact.

Peter Diamandis frames GLP-1s not just as weight-loss drugs but as the "very first longevity drug." By addressing metabolic unhealthiness and excess visceral fat—known life-shortening factors—these drugs represent a major step towards extending human healthspan, with more advanced versions already in development.

The tech world is fixated on trivial AI uses while monumental breakthroughs in healthcare go underappreciated. Innovations like CRISPR and GLP-1s can solve systemic problems like chronic disease and rising healthcare costs, offering far greater societal ROI and impact on longevity than current AI chatbots.

While AI dominates headlines, GLP-1 drugs could have a more profound and immediate impact on society. They address the core mechanism of desire ("wanting less"), with applications for obesity, addiction, and compulsive behaviors that could fundamentally reshape public health and daily life.

Scott Galloway argues GLP-1 drugs (like Ozempic) will have a greater societal impact than AI. By tackling obesity, they could halve U.S. healthcare costs, help solve the deficit, and even curb addictions, making them a profoundly transformative technology.